文献速递流行病学与生物统计真实世界研究与卫生经济

评估美国男男性行为者中淋病经验性治疗应改变耐药流行率阈值:成本效果分析

Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis.
PubMed 文献 · PLoS Med · 2024-07-08

研究建立淋病多耐药株传播模型,评估美国男男性行为者中不同经验性治疗切换阈值对淋病相关成本与质量调整生命年的影响。结果显示,在3种抗生素可用情景下,切换阈值在1%至10%间变化对年病例数、总成本或总QALY损失无实质性影响;若未来新抗生素可用,较低切换阈值可改善人群净健康效益,若同时有药敏试验指导复治,阈值设为1%至2%可最大化净健康效益。

要点

  • 在3种抗生素可用情景下,切换阈值1%至10%对淋病年病例数、总成本或总QALY损失无实质性影响。
  • 若未来新抗生素可用,选择较低切换阈值可改善人群净健康效益。
  • 若同时有药敏试验指导复治,切换阈值设为1%至2%可最大化人群净健康效益。

核心结论

  • 改变一线抗生素切换阈值可能不会实质性改变淋病相关的健康和经济结局。
  • 当预期新抗生素很快可用,或除未来新型抗生素外还有药敏试验指导复治方案时,可降低切换阈值。

研究设计与样本

  • 建立淋病多耐药株传播模型,预测美国男男性行为者中不同切换阈值下淋病相关成本与QALY损失。
  • 模型计入症状、诊断、治疗及后遗症的成本与失能权重,并将成本与QALY合并为净健康效益(NHB)指标。

主要发现

  • 在3种抗生素可用情景下(2种适合一线治疗、1种仅适合耐药感染复治),切换阈值在1%至10%间变化对淋病年病例数、总成本或总QALY损失无实质性影响。
  • 若未来新抗生素可用,选择较低切换阈值可改善人群NHB。
  • 若同时有药敏试验指导一线治疗失败后的复治方案,切换阈值设为1%至2%预期可最大化人群NHB。

局限性

  • 分析仅关注男男性行为者人群,未考虑疫苗和快速药敏试验常规用于指导一线治疗等干预措施的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since common diagnostic tests for gonorrhea do not provide information about susceptibility to antibiotics, treatment of gonorrhea remains empiric. Antibiotics used for empiric therapy are usually changed once resistance prevalence exceeds a certain threshold (e.g., 5%). A low switch threshold is intended to increase the probability that an infection is successfully treated with the first-line antibiotic, but it could also increase the pace at which recommendations are switched to newer antibiotics. Little is known about the impact of changing the switch threshold on the incidence of gonorrhea, the rate of treatment failure, and the overall cost and quality-adjusted life-years (QALYs) associated with gonorrhea. METHODS AND FINDINGS: We developed a transmission model of gonococcal infection with multiple resistant strains to project gonorrhea-associated costs and loss in QALYs under different switch thresholds among men who have sex with men (MSM) in the United States. We accounted for the costs and disutilities associated with symptoms, diagnosis, treatment, and sequelae, and combined costs and QALYs in a measure of net health benefit (NHB). Our results suggest that under a scenario where 3 antibiotics are available over the next 50 years (2 suitable for the first-line therapy of gonorrhea and 1 suitable only for the retreatment of resistant infections), changing the switch threshold between 1% and 10% does not meaningfully impact the annual number of gonorrhea cases, total costs, or total QALY losses associated with gonorrhea. However, if a new antibiotic is to become available in the future, choosing a lower switch threshold could improve the population NHB. If in addition, drug-susceptibility testing (DST) is available to inform retreatment regimens after unsuccessful first-line therapy, setting the switch threshold at 1% to 2% is expected to maximize the population NHB. A limitation of our study is that our analysis only focuses on the MSM population and does not consider the influence of interventions such as vaccine and common use of rapid drugs susceptibility tests to inform first-line therapy. CONCLUSIONS: Changing the switch threshold for first-line antibiotics may not substantially change the health and financial outcomes associated with gonorrhea. However, the switch threshold could be reduced when newer antibiotics are expected to become available soon or when in addition to future novel antibiotics, DST is also available to inform retreatment regimens.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Yin X, Li Y, Rönn MM, et al. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLoS Med. 2024. PMID: 38976754. doi:10.1371/journal.pmed.1004424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。